A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT07365241

Public ClinicalTrials.gov record NCT07365241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Study identification

NCT ID: NCT07365241
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AbbVie; Industry
Enrollment: 531 participants

Conditions and interventions

Conditions

Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 1, 2026
Primary completion: Aug 31, 2030
Completion: Aug 31, 2030
Last update posted: Sep 1, 2026

2026 – 2030

United States locations

U.S. sites: 32
U.S. states: 19
U.S. cities: 30

Facility	City	State	ZIP	Site status
Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063	Birmingham	Alabama	35243	Recruiting
Usa Mitchell Cancer Institute /ID# 280198	Mobile	Alabama	36604	Recruiting
City Of Hope - Phoenix /ID# 281323	Goodyear	Arizona	85338	Recruiting
City of Hope National Medical Center /ID# 281322	Duarte	California	91010	Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396	Irvine	California	92618	Recruiting
Florida Cancer Specialists & Research Institute - South /ID# 281387	Fort Myers	Florida	33901	Recruiting
Orlando Health Cancer Institute /ID# 280418	Orlando	Florida	32806	Recruiting
Moffitt Cancer Center /ID# 279732	Tampa	Florida	33612	Recruiting
City Of Hope - Atlanta /ID# 279929	Newnan	Georgia	30265	Recruiting
OSF St. Francis Medical Center /ID# 279930	Peoria	Illinois	61637-0001	Recruiting
Springfield Clinic - First /ID# 281309	Springfield	Illinois	62702	Recruiting
City Of Hope - Chicago /ID# 281335	Zion	Illinois	60099	Recruiting
Franciscan St. Francis Health /ID# 279788	Indianapolis	Indiana	46237	Recruiting
Dana-Farber Cancer Institute /ID# 279690	Boston	Massachusetts	02215	Recruiting
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955	Grand Rapids	Michigan	49503	Recruiting
Minnesota Oncology - Edina Clinic /ID# 280698	Edina	Minnesota	55435	Recruiting
FirstHealth of the Carolinas- Speciality Center /ID# 279857	Pinehurst	North Carolina	28374	Recruiting
Oncology Hematology Care - Fairfield /ID# 280641	Fairfield	Ohio	45014	Recruiting
Willamette Valley Cancer Institute and Research Center /ID# 280617	Eugene	Oregon	97401	Recruiting
St. Lukes University Hospital /ID# 280204	Bethlehem	Pennsylvania	18015	Recruiting
Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619	Knoxville	Tennessee	37909	Recruiting
University Of Tennessee Medical Center /ID# 279896	Knoxville	Tennessee	37920	Recruiting
Baptist Memorial Hospital /ID# 281405	Memphis	Tennessee	38120	Recruiting
SCRI Oncology Partners /ID# 279779	Nashville	Tennessee	37203	Recruiting
Vanderbilt University Medical Center /ID# 280169	Nashville	Tennessee	37232	Recruiting
The University of Texas MD Anderson Cancer Center /ID# 280070	Houston	Texas	77030	Recruiting
Texas Oncology - Northeast Texas /ID# 280642	Tyler	Texas	75702	Recruiting
Blue Ridge Cancer Care - Blacksburg /ID# 281583	Blacksburg	Virginia	24060	Recruiting
Virginia Cancer Specialists - Fairfax /ID# 280710	Fairfax	Virginia	22031	Recruiting
Shenandoah Oncology /ID# 280699	Winchester	Virginia	22601	Recruiting
West Virginia University Hospitals /ID# 279883	Morgantown	West Virginia	26506	Recruiting
University of Wisconsin /ID# 279909	Madison	Wisconsin	53792-0001	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07365241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07365241 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →